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Abstract
Cellular DNA is not a uniform target for DNA-reactive drugs. At the nucleotide level, drugs recognize and bind short motifs of a few base
pairs. The location of drug adducts at the genomic level depends on how these short motifs are distributed in larger domains. This aspect,
referred to as region specificity, may be critical for the biological outcome of drug action. Recent studies demonstrated that certain minor
groove binding (MGB) drugs, such as bizelesin, produce region-specific lesions in cellular DNA. Bizelesin binds mainly T(A/T)4A sites,
which are on average scarce, but occasionally cluster in distinct minisatellite regions (200–1000 bp of f 85–100% AT), herein referred to as
AT islands. Bizelesin-targeted AT islands are likely to function as strong matrix attachment regions (MARs), domains that organize DNA
loops on the nuclear matrix. Distortion of MAR-like AT islands may be a basis for the observed inhibition of new replicon initiation and the
extreme lethality of bizelesin adducts ( < 10 adducts/cell for cell growth inhibition). Hence, long AT-islands represent a novel class of critical
targets for anticancer drugs. The AT island paradigm illustrates the potential of the concept of regional targeting as an essential component of
the rational design of new sequence-specific DNA-reactive drugs. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction: The concept of region-specific DNA
damage
Recent developments of new anticancer therapeutic strat-
egies emphasize specific cellular targets. Pointed interven-
tions exploiting molecular differences between tumor and
normal cells promise better treatment selectivity. Nonethe-
less, killing tumor cells, rather than just re-regulating their
growth, remains the ultimate clinical objective. Damage to
cellular DNA by nonspecific drugs is a clinically proven,
although definitely not ideal, ‘‘lethal’’ strategy. This review
discusses alternative lethal strategies based on targeting
distinct critical regions of cellular DNA with small mole-
cule, sequence-specific agents.
Cellular DNA is not a uniform target for DNA-reactive
drugs. At the nucleotide level, drugs recognize and bind
short motifs of a few base pairs (sequence specificity). The
location of drug adducts at the genomic level depends on
how these short motifs are distributed in larger domains
(region specificity). Region-specific targeting signifies not
only the ability to damage a desired critical target that may
have distinct structural and/or functional properties, but
also implies limited collateral damage elsewhere in the
genome. DNA lesions in critical domains of cellular DNA
are likely to have grave biological consequences. In con-
trast, damage to nonessential targets may contribute little to
killing cancer cells, yet result in adverse effects in normal
cells [1,2]. DNA-reactive drugs currently in the clinic,
which bind to cellular DNA indiscriminately, cannot be
region-specific [1]. Moreover, the profound majority of
adducts formed by such drugs are with macromolecules
other than DNA [1,3]. Increased treatment selectivity could
be anticipated for the treatment strategies that: (i) eliminate,
or at least limit, nonessential collateral damage and (ii)
result in drug-induced damage localized to critical regions
of the genome.
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2. The potential of sequence-specific small molecules for
region-specific DNA damage
Progress in the rational design of sequence-specific
molecules [4–8], in particular the elucidation of base-pair-
ing rules for pyrrole–imidazole polyamides [4,9–11], has
allowed for the recognition of relatively long discrete motifs
of several base pairs. In principle, agents of this level of
sequence specificity should enable region-specific targeting
of individual genes (‘‘anti-gene’’ strategy), which necessi-
tates the recognition of a single site in the genome. Thus far,
‘‘anti-gene’’ strategies have been pursued with triple-helix-
forming oligonucleotides (TFO) or oligonucleotide-mimick-
ing compounds [12–14]. These efforts, although intensive,
were mainly limited to model systems and have not yet
resulted in agents capable of in vivo activity in tumor-
bearing animals.
Sequence-specific agents that do exhibit promising in vivo
antitumor activities are found among minor groove binding
(MGB) drugs. Studies by us and other researchers demon-
strated that AT-specific anticancer drugs, such as tallimustine,
the cyclopropylpyrroloindole (CPI) family (such as adozele-
sin and bizelesin, Fig. 1), and strand scission enediyne agents
exhibit a remarkable sequence specificity with intracellular
DNA [15–23]. Several of these AT-specific MGBs are in
clinical trials [24–30].
The importance of determining which specific domains
are damaged by DNA-reactive drugs has been recognized
[31–33]. However, our investigations were the first that
established a systematic approach that allows us to assess
the potential of sequence-specific agents for localized da-
mage in longer stretches of DNA (i.e., region specificity).
Our approach combines molecular pharmacology and
bioinformatics tools and comprises the following ele-
ments: (i) experimental determination of drug sequence
specificity (binding motifs), (ii) in silico analysis of
binding motif distribution at the genomic level to identify
which genomic regions may be particularly vulnerable to
a specific drug, and, (iii) the experimental verification of
such predictions by mapping drug sites and quantitating
drug-induced lesions in selected specific regions. Consis-
tent results with drugs of divergent sequence specificities
strongly suggest the utility of this approach [19,21,34–
38].
Fig. 1. AT-specific drugs of the CPI family (bizelesin, adozelesin and U78779), and tallimustine and their preferred binding motifs [18,19,21,35]. U78779
prefers mixed AT–GC motifs (top motif is an example), although the drug binds also pure AT motifs (bottom). Asterisks indicate covalently adducted
bases.
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2.1. Region-specific damage to AT islands by bizelesin: a
proof of principle
Our studies demonstrated for the first time that sequence-
specific small molecules can produce a nonrandom, region-
specific damage to genomic DNA. Importantly, these find-
ings have been made with bizelesin, a CPI drug with
demonstrated antitumor activity in vivo [39] and indications
of antitumor efficacy in patients in Phase I trials (Ref. [28]
and Dr. E. Rowinsky, personal communication).
Bizelesin binds mainly to T(A/T)4A sites in cellular DNA,
forming interstrand crosslinks (Fig. 1), although some mono-
adducts are also possible [18]. Long-range in silico analysis
shows that at the genomic level, the bizelesin binding motif
T(A/T)4A is found on average 2.8 times/250 bp. However,
approximately every 106 bp, a hot spot is found with high
Fig. 2. (A) Bizelesin binding sites in genomic DNA are infrequent but clustered in long AT islands. Examples of in silico analysis of the distribution of bizelesin
binding motif. The histograms depict the number of exact matches to the bizelesin motif in bins of 250 bp along the indicated GenBank sequences. (B) TATA
boxes, transcription factor (TF) binding sites and other short AT tracts are insignificant as bizelesin targets. Top: The distribution of bizelesin binding sites and
the consensus motifs for bizelesin-compatible AT elements around an AT island (in GenBank Z80771). Bottom: The density of bizelesin binding motif in long
AT islands markedly exceeds genome average. TATA boxes and bizelesin-compatible TF binding sites are even less frequent than this low average. (Note the
expanded scale for TATA boxes and TF. Adapted with permission from Ref. [38]).
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clusters of potential binding sites (up to 99 sites/250 bp, Fig.
2A). These clusters of bizelesin motifs are in 200–1000 bp
long islands of highly (up to 100%) AT-rich DNA. Notably,
compared to these long AT islands, various short AT-tracts are
unlikely to be significant as a target for bizelesin (Fig. 2B).
Actual bizelesin lesions show an excellent agreement
with the in silico predictions based on the distribution of
bizelesin binding motifs T(A/T)4A [21,38]. Fig. 3 illustrates
the sites of predicted and actual drug lesions in the naked
DNA of a model AT island. Bizelesin was f 100-fold more
reactive with this AT island than with a model non-AT island
DNA [21,38]. Consistent with the in silico predictions, the
same preference for long AT islands is maintained in drug-
treated cells. The examples of data illustrate a large differ-
ential in lesions in AT islands and lesions in non-AT islands
and in bulk DNA, in particular for the lowest drug concen-
trations (Fig. 4A). The predictive power of the in silico
analysis is underscored by an excellent correlation between
the actual lesions and the densities of drug binding motifs
(Fig. 4B). Bizelesin is the first anticancer drug for which
such a differential, region-specific damage has been docu-
mented. These results provide a proof of principle that
targeting distinct noncoding regions is feasible.
2.2. Is region-specific damage to AT islands a common
property of other AT-specific drugs?
Our studies with other drugs, where computational pre-
dictions were also fully corroborated by experimental deter-
minations of drug adducts, allow us to propose the general
requirements for a region-specific DNA damage. High
motif specificity, such as that of bizelesin, is essential
for a significant preference for AT islands [21]. U78779,
an analog that binds at (A/T)6A, is also highly preferential
for long AT islands, despite the fact that it prefers mixed
A/T–G/C sequences [35,41]. The less sequence-specific
adozelesin, which recognizes N(A/T)3A and NN(A/T)2A
sites [21], retains some preference for AT-rich islands (Fig.
5). However, in contrast to bizelesin, adozelesin binding
to AT tracts outside of the long AT islands is substantial,
and adozelesin cannot be regarded as a region-specific
agent.
Sequence specificity alone is insufficient for region
specificity. Tallimustine has a strong preference for 5V-
TTTTGPu-3V[19]. Consistent with this stringent sequence,
the tallimustine motif is approximately 10 and 100 times
less frequent than motifs for bizelesin and adozelesin,
respectively (Fig. 5) [19]. However, the infrequent talli-
mustine sites are distributed nearly randomly throughout
the genome, which explains the experimentally determined
lack of region specificity [19]. Drugs like tallimustine,
which are devoid of any regional specificities, do not offer
any significant advantages over typical non-sequence-spe-
cific DNA-reactive agents. As shown for cisplatin, the
latter, nondiscriminating drugs cannot be region-specific
due to their low specificity of DNA recognition and the
ubiquitous distribution of the potential binding sites
(mainly GG clusters). Still, even these marginal specific-
Fig. 3. Predicted (middle panel) and actual bizelesin-induced lesions in the naked DNA of a model AT island. The triangles in the middle panel indicate the
positions of the G/C pairs that flank the 100% AT core of this AT island, while each vertical spike corresponds to an exact match of the sequence to drug
binding motif. Experimental panels (top and bottom) show drug sites monitored as sub-bands with singly end-labeled DNA after the conversion of adducts to
strand breaks (adapted with permission from Ref. [38]).
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ities translate into more platinum adducts formed in GC-
rich regions that contain large number of drug binding
motifs. [37]. The ability to correctly predict such rather
subtle effects points to the general utility of the in silico
approach for drugs from both high- and low-ends of
sequence specificities.
3. Long AT islands as critical regions
Targeting of AT islands is more lethal by several orders of
magnitude than non-region-specific damage to DNA [18,19,
21,36,40,41]. Region-specific bizelesin and U78779, which
also targets AT islands, need to form very few lesions ( < 10
DNA adducts/cell) to block cell growth (Table 1). Adducts
by AT-specific, but non-region-specific, tallimustine are
markedly less lethal (f 200 adducts/cell). In striking con-
trast to AT-specific drugs, non-sequence-specific classical
drugs need to form several thousands of DNA lesions/cell to
inhibit cell growth. It is clear that damage to AT islands by
CPI drugs impedes functions that are crucial for the growth
of cancer cells.
3.1. Matrix associated regions (MARs) and AT islands
Although specific functions of the individual AT-islands
identified, as bizelesin targets remain mostly undefined,
several lines of evidence suggest that these domains can
function as MARs. MAR domains are specialized loci that
anchor cellular DNA to the nuclear matrix, a proteinaceous
scaffolding that organizes chromatin fibers into looped
domains participating in the spatial organization of chromo-
some territories [42–45] and is the site of DNA replication
and transcription [42,44–48]. A high MAR potential is a
consistent attribute of AT island domains. In addition,
evidence of actual MAR function is available for several
loci [38]. The MAR attributes positively and significantly
correlate with the number of bizelesin binding sites and
actual levels of lesions in these AT islands [38].
3.2. Inhibition of DNA replication and damage to MAR-like
AT islands
Bizelesin-induced damage to MAR-like AT islands may
explain the observed specific inhibition of new replicon
initiation [40,49]. Intriguingly, only one to two bizelesin
adducts per f 106 bp (i.e., per several typical replicons) are
needed for a genome-wide inhibition of replicon initiation
[40]. Thus, bizelesin adducts seem to exert inhibitory effects
on cellular DNA replication at a substantial distance from
their actual location. By contrast, in a cell-free system, only
modest inhibition, consistent with a local blockade to chain
elongation, is observed [40].
This differential pattern of anti-replicative properties
could be explained by the functional association of cellular
replication, but not cell-free replication, with the nuclear
matrix [42,50]. In the cell, strong MAR domains form the
boundaries of replication factories. An unperturbed MAR
structure seems essential for the near simultaneous firing of
each replicon clustered in a given replication factory
[50,51]. The blocked initiation of several replicons by a
single bizelesin adduct spaced every 106 bp is consistent
with (i) an average size of a replication factory (f 106 bp)
[50], (ii) the occurrence of strong MAR domains (f 1/106
Fig. 4. Bizelesin preferentially damages MAR-like AT islands versus non-
AT island regions in leukemic CEM cells (adapted with permission from
Refs. [21,38] with additional unpublished data). (A) Examples of region-
specific lesions monitored by quantitative polymerase chain reaction stop
assay in DNA from drug-treated CEM cells in AT islands (ApoB MAR,
n; Fra16D, .) in comparison to lesions a non-AT island (in h-globin, )
and in bulk DNA (5). (B) Correlation between the density of the pre-
dicted bizelesin binding sites and actual levels of region-specific adducts.
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bp)[50–54], and (iii) the occurrence of bizelesin hot spot
AT-islands (also f 1/106 bp) [38]. Further investigations
are needed to test the possibility that lesions in MAR-like
AT islands distort the integrity of replication factories.
3.3. Genetic instability of AT islands and drug targeting
Bizelesin-targeted MAR-like AT islands are minisatel-
lites [38], which are, in general, known to be genetically
unstable elements. Polymerase slippage on repetitive
sequences and/or amplification may expand such domains
by many kbp [55–57]. Well-known elements of genomic
instability, the AT-rich fragile sites Fra16B and Fra16D, are
among bizelesin targeted AT islands [38], and their vulner-
ability has been verified by recent experimental determina-
tions (c.f., Fig. 4, [76] and Woynarowski et al., unpublished
data). Importantly, repeat expansion of such inherently
unstable domains and associated downstream rearrange-
ments are thought to contribute to tumorigenic phenotype.
AT-rich sites of genomic instability have been particularly
implicated in leukemias and lymphomas [55,58–62],
including acute lymphoblastic leukemia (ALL), the most
frequent pediatric malignancy [63–66]. The inherent insta-
bility of AT islands may thus give rise to fundamental
differences among various cancer and normal lines.
Our recent data prompted us to investigate the possibility
that such differences in the abundance and/or function of AT
islands might be associated with differential responses to
AT-island targeting drugs. Whereas bizelesin is generally
cytotoxic in picomolar concentrations, some tumor cell lines
appear to be significantly (P < 0.05) hypersensitive than
some other tumor and normal cell lines examined ([76]
and Woynarowski et al., unpublished data). For human
leukemia CEM and normal WI-38 cells, we additionally
demonstrated that the differential sensitivity to bizelesin is
not due to any differences in drug reactivity with cellular
DNA, or lesion repair ([76] and Woynarowski et al.,
unpublished data). Our recent data show also that Fra16B
Fig. 5. Examples of the distribution of drug binding motifs at the genomic level (in silico analysis) for adozelesin, tallimustine and cisplatin. The histograms
depict the number of exact matches to the bizelesin motif in bins of 250 bp along the indicated GenBank sequences. Average hits/250 bp in the genome are also
given for each drug. The examples shown are for GenBank sequences Z79699 L78833 (data for tallimustine and cisplatin were adapted with permission from
Ref. [19]). The arrow points to one of the long AT island, that is among bizelesin targets (c.f. Fig. 3).
Table 1









Bizelesin AT-specific and region-specific (AT islands) 0.6 10 12 0.88 2 [21,41]
U78779 AT-specific and region-specific (AT islands) 3.3 10 12 0.22 2 [34,35,41]
Tallimustine AT-specific, non-region-specific 3.5 10 9 0.022 220 [41]
Cisplatin G/C preferring, non-region-specific 1.5 10 6 0.032 14,000 [75]
a Drug concentration inhibiting net cell growth by 50% determined by the MTT assay.
b Estimated by linear extrapolation of lesion frequencies/kbp/AM to the GI50 concentration assuming 2.9 109 bp/cell (rounded values).
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AT islands are more abundant in hypersensitive leukemic
CEM cells, but not in non-hypersensitive normal WI-38 and
several other cell lines. We speculate that expansion
(increased abundance) of AT islands, such as these fragile
sites, may sensitize certain tumors to bizelesin-type drugs by
increasing the number of potential drug binding sites. Alter-
natively, while all the identified bizelesin-targeted AT islands
are capable of MAR function, the actual association of such
domains with the nuclear matrix may differ among various
cell types [42,67]. For instance, the Fra16B and c-myc MAR
domains co-localize mainly with matrix DNA in bizelesin-
sensitive cancer CEM cells but not in normal WI-38 cells
([76] and Woynarowski et al., unpublished data). Loop
localization of the c-myc was also found with other normal
cells [68]. It seems plausible that damage to a given AT island
may be more critical for those cell types, in which such
sequences are associated with the nuclear matrix and function
as MARs. Studies are underway to verify these possibilities.
4. Relevance of AT island targeting to anticancer
therapies and perspectives for region-specific targeting
of other repetitive sequences
There are several reasons why targeting AT islands may
offer potential therapeutic benefits over non-region-specific
classical DNA-reactive drugs used in the clinic. First,
certain abnormal AT islands, such as expanded fragile sites
Fra16B and Fra16D, are thought to contribute to tumori-
genic phenotypes. Although this aspect still requires sub-
stantial investigation, AT-island targeting may offer
increased selectivity for such tumors. Second, rapid cell
proliferation is a hallmark of many tumors, especially these
of pediatric origin. Rapidly replicating cells should be
preferentially eliminated by highly localized lesions in
replication-related regions, such as MAR-like AT islands.
In contrast, typical DNA-reactive drugs extensively damage
regions that are also crucial for functioning of nonreplicat-
ing cells. Finally, treatment with classical DNA-reactive
drugs results in thousands (104–105) of low-lethality but
mutagenic DNA lesions/cell in normal tissues [1]. Conse-
quently, secondary, drug-induced tumors are a common and
dramatic problem, pertinent in particular to children who
typically live for many years after the eradication of their
primary cancers [69]. In contrast to classical drugs, lesions
in AT islands are extremely lethal [19,21] (see above).
Lethal lesions, by definition, cannot lead to mutations.
Hence, therapies based on AT island targeting should be
associated with a reduced risk of secondary tumors.
Beyond the AT island paradigm, targeting of other
repetitive and potentially critical domains may also offer
significant benefits. One prominent example of a critical
and highly abundant target is telomeric DNA with its
(TTAGGG)n repeats. Telomeric sequences, both terminal
and interstitial, may have a role in chromosomal aberrations
and can be amplified in cancer cells in proportion to the
invasive and metastatic potential [70,71]. Maintaining telo-
mere length, usually by the specialized enzyme telomerase,
gives a growth advantage to cancer cells by extending their
life span [72–74]. Conversely, damage to telomeres should
be detrimental to cancerous growth [72–74]. The modular
structure of the telomeric repeats consisting of discrete A/T
and G/C blocks should facilitate the design of small-mole-
cule region-specific drugs with sufficiently high preferences
for these motifs.
5. Conclusions: Significance of region specificity for
rational drug design and targeting
Targeting specific domains in the genome should limit
various adverse effects of current anticancer therapies,
which use non-region-specific DNA-reactive drugs. In par-
ticular, further exploration of distinct repetitive sequences in
noncoding regions as potentially critical targets should
generate leads for better, more selective drugs. In contrast
to targeting unique sites in specific genes, domains of re-
petitive sequences with clusters of drug binding sites con-
stitute highly abundant targets that can be selectively
targeted with agents of less than ideal specificity. Bizelesin
is the first example of a drug that not only is region-specific
in tumor cells but also exhibits antitumor activity in vivo
and promising clinical properties. Region-specific damage
to MAR-like AT islands by bizelesin provides a proof of
principle that targeting repetitive sequences crucial for the
survival of cancer cells is feasible.
The significance of sequence specificity at the nucleotide
level is generally recognized, even if a given drug is not
explicitly designed to target specific domains. The estab-
lished prerequisites of drug regional preferences [19,21,37]
point to the definite need for appreciable drug binding
specificity. Equally important, however, is genomic compo-
sition. Tallimustine is not region-specific because its highly
specific motif is distributed nearly randomly and infre-
quently throughout the genome. Bizelesin is region-specific
because its binding motifs are nonrandomly distributed,
with clusters in repetitive sequences of AT islands and
infrequent sites elsewhere.
In contrast to drug sequence specificity, drug regional
preferences at the genomic level are usually not addressed or
are taken for granted. The reviewed studies emphasize that
lesions distribution may critically depend on the genome
itself, and how misleading it could be to rely on the
seemingly intuitive opinions, such as ‘‘. . .the more sequence
specificity the better. . .’’ or that ‘‘. . .AT-specific drugs
equally target various AT elements’’. In contrast to such
misleading or downright incorrect subjective judgments, the
developed bioinformatics tools demonstrate the ability to
accurately predict and verify which genomic elements are
likely and which are unlikely to be targeted by specific
drugs. This rigorous and objective analysis is generally
applicable to any kind of DNA targeting. In a not too
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distant future, it should be possible to analyze the entire
human genome in that way. Bioinformatics tools, such as
those used in our studies, can accelerate the development of
new region-specific molecules against various targets. The
rapid optimization of drug binding motif by in silico
analysis should limit the number of compounds that need
to be synthesized, and eliminate many prototypes that would
unlikely have any regional preferences. We feel that once
the concept of regional targeting is systematically devel-
oped, it should become an essential component of the
rational design of new sequence-specific drugs.
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